A summary of Nature's anti-tumor drug research and development achievements in the past decade

Oncology drugs are the top drugs in the prescription drug market by total sales, and these sales have grown steadily over the past decade

Oncology drugs have grown steadily over the past decade Changes in the oncology drug market over the past decade

1.

1.

Roche surpassed all rivals Celgene and Novartis in sales between 2010 and 2019, followed by Bristol-Myers Squibb, Merck, fourth and fifth Johnson & Johnson, AstraZeneca, Pfizer, Eli Lilly and Takeda

Figure 1a.

2.

2.

Three biologics CD20 specific monoclonal antibody Rituxan VEGF specific monoclonal antibody Avastin HER2 specific monoclonal antibody Herceptin main source of sales Roche

Notably, starting in 2014, Roche's Herceptin "follow-on" products: the HER2-specific monoclonal antibody Perjeta (Pertuzumab) and the HER2-specific antibody-drug conjugate Kadcyla (trastuzumab) anti-emtansine) sales are very high

The company .

Figure 1b.

3.

3.

Of the 172 anti-tumor drugs collected , 49 generated sales of over $1 billion in each of the years 2010-2019 Blockbuster drugs with annual sales of over $5 billion were generated over time more and more income

Figure 2a.

4.

4.

To illustrate the research progress of anticancer drugs in the past decade, you can refer to the income of a single drug in a class of drugs

Targeted therapy Small molecule kinase inhibitors and monoclonal antibodies Market share of chemotherapy declined by 17% as patent protection of older products expired or some of their uses were replaced by newer drugs such as targeted therapy Market share of targeted therapy increased in total $56 billion

Revenues from targeted therapies have grown substantially over the past decade

Sales of such drugs, such as PD-1/PD-L1 inhibitors Keytruda and Opdivo, have grown to $25 billion since the first checkpoint inhibitor was approved in 2011
.

Conclusion and Outlook

Conclusion and Outlook

The enormous efforts made by biotech and pharmaceutical companies in cancer treatment have yielded remarkable results
.
The development and marketing of some key drugs is critical to the success of investment in the oncology sector , and the sales of one or a portion of the blockbuster drugs have helped some companies to occupy a place in the top 10 positions in the oncology field
.

Developing and marketing some key drugs is critical to the success of oncology investments

Between 2010 and 2019, the rise of immune checkpoint inhibitors and the integration of targeted kinase inhibitors and monoclonal antibodies constituted the main income for the oncology investment segment
.
After 2010, a large portion of the revenue for these classes of drugs came from blockbuster drugs protected by patents
.
Mainly include Merck's Keytruda, BMS's Opdivo, Pfizer's Ibrance, AbbVie and Johnson & Johnson's Imbruvica
.
For old blockbusters like Avastin, Rituximab and Herceptin, biosimilar competition has begun and will lead to new market competition
.

Immune checkpoint inhibitor- targeted kinase inhibitor monoclonal antibody blockbuster biosimilar competition has begun and will lead to new market competition

In the future, companies may look to expand key indications for leading drugs, including identifying subgroups of responsive patients based on biomarkers rather than the tissue of origin of the cancer
.
The increasing understanding of tumors and the improvement of methods to detect and localize key carcinogens in the clinic will facilitate the elucidation of new targets
.
As innovation develops, we expect the market for oncology drugs to expand further
.

In the future, companies may look to expand key indications for leading drugs, including identifying subgroups of responsive patients based on biomarkers rather than the tissue of origin of the cancer
.
New Targets With the development of innovation, we expect the market for oncology drugs to expand further
.

references:

references:

1.
Oncology remains market- leading therapy area with $142bn sales in 2019: https:// market- leading- therapy- area-142bn-sales-2019.

1.
Oncology remains market- leading therapy area with $142bn sales in 2019: https:// market- leading- therapy- area-142bn-sales-2019.

2.
Supplementaryinformation is available for this paper at https://doi.
org/10.
1038/d41573-021-

2.
Supplementaryinformation is available for this paper at https://doi.
org/10.
1038/d41573-021-